
Now that Cardiff Oncology Inc’s volume has hit 1.31 million, investors get a glimpse of its size.
A new trading day began on August 12, 2025, with Cardiff Oncology Inc (NASDAQ: CRDF) stock priced at $2.37, up 4.29% from the previous day
A new trading day began on August 12, 2025, with Cardiff Oncology Inc (NASDAQ: CRDF) stock priced at $2.37, up 4.29% from the previous day
Cardiff Oncology Inc (NASDAQ: CRDF) on Monday, plunged -4.92% from the previous trading day, before settling in for the closing price of $2.64. Within the
As on Thursday, Cardiff Oncology Inc (NASDAQ: CRDF) started slowly as it slid -4.82% to $2.37, before settling in for the price of $2.49 at
On Monday, Cardiff Oncology Inc (NASDAQ: CRDF) was -6.05% drop from the session before settling in for the closing price of $3.97. A 52-week range
Witnessing the stock’s movement on the chart, on Thursday, Cardiff Oncology Inc (NASDAQ: CRDF) had a quiet start as it plunged -3.50% to $4.14, before
Cardiff Oncology Inc (NASDAQ: CRDF) on Monday, plunged -8.64% from the previous trading day, before settling in for the closing price of $4.28. Within the
Witnessing the stock’s movement on the chart, on Wednesday, Cardiff Oncology Inc (NASDAQ: CRDF) set off with pace as it heaved 7.28% to $4.42, before
On Tuesday, Cardiff Oncology Inc (NASDAQ: CRDF) opened higher 7.95% from the last session, before settling in for the closing price of $3.65. Price fluctuations
On Thursday, Cardiff Oncology Inc (NASDAQ: CRDF) opened higher 1.95% from the last session, before settling in for the closing price of $3.59. Price fluctuations
On Tuesday, Cardiff Oncology Inc (NASDAQ: CRDF) opened higher 11.43% from the last session, before settling in for the closing price of $3.15. Price fluctuations
Newsdaemon.com is a Business and Stock news website that covers extensive information on Stock markets and Equities. One of the key emphases of this portal is to widen readers’ knowledge of public and private capital sharing, both in updates and broad analysis.
Copyright © 2024 News Daemon, All rights reserved.